Latest and Past News
-
Reimbursement of Altuviiio recommended, but…
MONTRÉAL, July 3, 2025 – In June, both Canada’s Drug Agency (CDA) and Quebec’s Institut national d’excellence en santé et en services sociaux (INESSS) released...
-
Kathy Mulder appointed to the Order of Canada
Montréal, July 1, 2025 – On this very special 2025 Canada Day, the CHS could not be prouder as, yesterday, Kathy Mulder, a long-acting volunteer...
-
NEW BOOKLET! All About Novel Therapies
The CHS is very proud to present its latest publication, the first component of its brand-new Novel Therapies Education Program. CLICK HERE to access the online booklet.
-
Health Canada approves Altuviiio
MONTRÉAL, March 31, 2025 – Health Canada has granted marketing approval to Altuviiio (efanesoctocog alfa) for the treatment of hemophilia A in children, adolescents and...
-
Hemgenix 4-year results show steady durability
MONTREAL, March 12, 2025 – Results from the HOPE-B trial for the hemophilia B gene therapy, Hemgenix, show steady expression of factor IX (FIX) four...
-
Development halts in first-generation gene therapies
MONTREAL, February 25, 2025 – On February 20, Pfizer announced that it was stopping development of its hemophilia B gene therapy, Beqvez. It cited “soft...
-
Novel treatments in bleeding disorders: The European Haemophilia Consortium Review
CLICK HERE to access the 2025 ISSUE ONE of the periodic review of novel treatments in hemophilia and other bleeding disorders by the European Haemophilia...
-
Now accepting applications for the James Kreppner Scholarship and Bursary Program
The competition for the James Kreppner Memorial Scholarship and Bursary Program is now open. DEADLINE TO APPLY: APRIL 30, 2025 CLICK HERE for all the details.
-
Your FEEDBACK matters to us!
The CHS is currently developing the next CHS Strategic Plan. We would appreciate your insights into how we can further our mission and enhance our...
-
Best wishes from the CHS!
Please CLICK HERE to read a special message from CHS President, Emil Wijnker, and Chief Executive Officer, Sarah Ford.
-
CHS survey of people with hemophilia A and their caregivers
In June and July 2024, the Canadian Hemophilia Society conducted an online survey regarding the lived experience of people with hemophilia A and their caregivers....
-
Rendez-vous 2025
The Canadian Hemophilia Society is delighted to invite you to attend Rendez-vous 2025 coming up May 1-4, 2025, in Winnipeg. CLICK HERE for a glimpse at the...
-
Biomarin limits marketing of its FVIII gene therapy, Roctavian
SAN RAFAEL, California, August 5, 2024 — Biomarin has announced that it will limit commercial, research and manufacturing programs for its factor VIII gene therapy...
-
Novel treatments in bleeding disorders: The European Haemophilia Consortium Review
CLICK HERE to access the 2024 ISSUE TWO of the periodic review of novel treatments in hemophilia and other bleeding disorders by the European Haemophilia...